Neogen Chemicals Limited sees a credit rating action

As of the latest reported quarter (Q4 FY26), Neogen Chemicals Limited’s consolidated Net Debt was Rs 1,325.0 Crores ^[1]. While the company reports consolidated EBITDA margins of 18.2% for the same period ^[2], the absolute consolidated EBITDA required to calculate the Net Debt/EBITDA ratio is not separately disclosed in the provided filings or KPI data.

Regarding internal leverage covenants, the specific threshold levels agreed upon with lenders for the rated bank facilities are not publicly disclosed in the provided regulatory filings or credit rating announcements ^[3].

Context and Implications

• Financial Position: The company’s consolidated Net Debt has increased from Rs 561.08 Crores in Q1 FY26 to Rs 1,325.0 Crores by Q4 FY26 ^[1]. This rise in leverage coincides with a significant expansion in Capital Work in Progress (CWIP), which grew from Rs 156.19 Crores to Rs 857.12 Crores over the same period ^[4].
• CRISIL Rationale: The recent downgrade to CRISIL A-/Negative reflects concerns regarding the liquidity impact of these capital-intensive projects, specifically delays in the battery chemicals project and the timing of insurance claim receipts ^[3].
• Disclosure Gap: While the credit rating action highlights "stretched working capital" as a primary driver for the downgrade ^[3], the specific financial covenants (such as maximum Net Debt/EBITDA or Debt/Equity limits) governing the Rs 680 Crore bank facilities ^[3] remain proprietary to the lender-borrower agreements and are not detailed in the company's public disclosures.

Neogen Chemicals Limited’s working capital cycle showed operational improvement in FY26, with both inventory and receivable days declining from their FY25 peaks. However, this trend does not mitigate the liquidity pressures highlighted by CRISIL, as the rating agency’s downgrade to CRISIL A-/Negative is driven by project-specific execution delays and insurance claim recovery issues rather than working capital inefficiency.

Working Capital Trend (Consolidated)

The company’s working capital metrics indicate a reversal of the deterioration seen in FY25, with FY26 levels returning to or improving upon FY24 benchmarks.

Alignment with CRISIL Liquidity Profile

The operational improvement in working capital does not align with the liquidity concerns cited by CRISIL. The rating downgrade reflects heightened financial risk stemming from two primary external factors:

• Project Execution: CRISIL explicitly cited delays in the battery chemicals project as a core reason for the rating action ^[3]. While the company has managed to reduce its inventory and receivable days, the capital intensity of the battery chemicals project—evidenced by the surge in Capital Work in Progress to Rs 857.12 Crores in FY26 from Rs 156.19 Crores in FY25 ^[9]—has placed significant pressure on the balance sheet.
• Insurance Claim Receipt: The delay in receiving insurance claims has constrained cash inflows, further pressuring liquidity ^[3].

The divergence between the working capital cycle and the liquidity profile is further highlighted by the sharp increase in payable days, which rose from 150.30 in FY25 to 240.90 in FY26 ^[8]. This suggests that the company is increasingly relying on extended credit from suppliers to manage its cash position, a strategy often employed when liquidity is tight.

Implications

• Cash Flow Pressure: Despite the reduction in inventory and receivable days, the company’s cash conversion remains volatile, with a consolidated cash conversion of -161.4% in FY26 ^[10]. The reliance on extended payables to manage liquidity is a structural risk that may limit future operational flexibility if supplier terms tighten.
• Liquidity Risk: The "Negative" outlook from CRISIL indicates that the market and rating agencies are prioritizing the resolution of project delays and insurance recoveries over improvements in standard working capital metrics. The company’s ability to stabilize its liquidity profile will likely depend on the successful commissioning of the battery chemicals project and the realization of pending insurance claims rather than further optimization of the current working capital cycle.